Furthermore, GW4869 administration also alleviates neuroinflammation post cerebral ischemia, ascertained by the decrease of CD86 and increase of CD206 in all test brain regions in GW4869-treated groups vs. DMSO-treated groups (Figures 7D–F). The gene discussed is CD86; the disease is Cerebral ischemia.